A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Inclusion Criteria: * Unequivocal histologically or cytologically confirmed diagnosis of metastatic or locally advanced NSCLC not amenable to treatment with surgical resection or combined chemoradiation * Disease progression during or after treatment with at least one prior systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Documentation of the presence of a KRAS G12C mutation * Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 10-15 (15 preferred) unstained, freshly cut, serial slides with an associated pathology report * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of \>= 12 weeks Exclusion Criteria: * Known hypersensitivity to any of the components of divarasib, or sotorasib or adagrasib * Malabsorption syndrome or other condition that would interfere with enteral absorption * Known concomitant second oncogenic driver * Mixed small-cell lung cancer or large cell neuroendocrine histology * Known and untreated, or active central nervous system (CNS) metastases * Leptomeningeal disease or carcinomatous meningitis * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures biweekly or more frequently * Any infection that, in the opinion of the investigator, coul…